Literature DB >> 3203059

Naproxen kinetics in synovial fluid of patients with osteoarthritis.

R Bruno1, A Iliadis, I Jullien, M Guego, H Pinhas, S Cunci, J P Cano.   

Abstract

1. The kinetics of naproxen in synovial fluid were studied in 407 osteoarthritic outpatients with knee effusion requiring aspiration, following a single 1100 mg oral dose of naproxen sodium. 2. The drug concentration-time profiles were described by a biexponential function. Naproxen entered synovial fluid rapidly, reaching a maximum concentration of 36 mg l-1 (Cmax) at 7.5 h. The first order input rate constant (kOs) was 0.41 +/- 0.15 h-1 with a lag time (tlag) of 0.24 +/- 0.36 h. 3. Elimination from the fluid was slow (t1/2 = 31 +/- 12 h) and appreciable drug concentrations were still measurable (27 mg l-1) after 24 h. 4. During once daily dosing of naproxen sodium, naproxen should accumulate in synovial fluid, a steady-state being achieved within a week of treatment. The predicted accumulation ratio based on trough concentration was 2.4.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203059      PMCID: PMC1386497          DOI: 10.1111/j.1365-2125.1988.tb03361.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Steady-state dosage regimen calculations in linear pharmacokinetics.

Authors:  A Iliadis; R Bruno; J P Cano
Journal:  Int J Biomed Comput       Date:  1986-05

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

Review 3.  Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics.

Authors:  W J Wallis; P A Simkin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

4.  Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.

Authors:  R Runkel; M Chaplin; G Boost; E Segre; E Forchielli
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

5.  Naproxen concentrations in serum, synovial fluid, and synovium.

Authors:  S Jalava; H Saarimaa; M Anttila; H Sundquist
Journal:  Scand J Rheumatol       Date:  1977       Impact factor: 3.641

6.  Total and free ketoprofen in serum and synovial fluid after intramuscular injection.

Authors:  P Netter; B Bannwarth; F Lapicque; J M Harrewyn; A Frydman; J N Tamisier; A Gaucher; R J Royer
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

7.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Authors:  L B Sheiner
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

8.  Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation.

Authors:  F A van den Ouweland; M J Franssen; L B van de Putte; Y Tan; C A van Ginneken; F W Gribnau
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

9.  Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis.

Authors:  L Aarons; R Salisbury; M Alam-Siddiqi; L Taylor; D M Grennan
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  9 in total
  7 in total

1.  Quantitative analysis of walking in patients with knee osteoarthritis: a method of assessing the effectiveness of non-steroidal anti-inflammatory treatment.

Authors:  O Blin; J Pailhous; P Lafforgue; G Serratrice
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

Review 2.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 3.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

5.  The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse.

Authors:  Anna Buus Frost; Frank Larsen; Susan Weng Larsen; Jesper Østergaard; Maj Halling Thomsen; Stefan Stürup; Pia Haubro Andersen; Claus Larsen
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

6.  Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.

Authors:  P Bertin; F Lapicque; E Payan; M Rigaud; F Bailleul; S Jaeger; R Treves; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Naproxen treatment inhibits articular cartilage loss in a rat model of osteoarthritis.

Authors:  David N Paglia; Deboleena Kanjilal; Yazan Kadkoy; Spiro Moskonas; Charlene Wetterstrand; Anthony Lin; Joseph Galloway; Jeffrey Tompson; Maya D Culbertson; J Patrick O'Connor
Journal:  J Orthop Res       Date:  2020-12-15       Impact factor: 3.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.